Johnson takes chair at Dendreon
This article was originally published in Scrip
Executive Summary
John Johnson, who became Dendreon's CEO in February this year (scripintelligence.com, 1 February 2012), has assumed the title of chair as well, ousting Dr Mitchell Gold as planned. Dr Gold will continue to serve as a director.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.